Cargando…
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the triggering of an aberrant host immune response, more so than on direct virus-induced cellular damage. To elucidate the immunopathology underlying COVID-19 severity, we perform cytokine and multiplex immune profil...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257697/ https://www.ncbi.nlm.nih.gov/pubmed/34226537 http://dx.doi.org/10.1038/s41467-021-24360-w |
_version_ | 1783718366183161856 |
---|---|
author | Vanderbeke, L. Van Mol, P. Van Herck, Y. De Smet, F. Humblet-Baron, S. Martinod, K. Antoranz, A. Arijs, I. Boeckx, B. Bosisio, F. M. Casaer, M. Dauwe, D. De Wever, W. Dooms, C. Dreesen, E. Emmaneel, A. Filtjens, J. Gouwy, M. Gunst, J. Hermans, G. Jansen, S. Lagrou, K. Liston, A. Lorent, N. Meersseman, P. Mercier, T. Neyts, J. Odent, J. Panovska, D. Penttila, P. A. Pollet, E. Proost, P. Qian, J. Quintelier, K. Raes, J. Rex, S. Saeys, Y. Sprooten, J. Tejpar, S. Testelmans, D. Thevissen, K. Van Buyten, T. Vandenhaute, J. Van Gassen, S. Velásquez Pereira, L. C. Vos, R. Weynand, B. Wilmer, A. Yserbyt, J. Garg, A. D. Matthys, P. Wouters, C. Lambrechts, D. Wauters, E. Wauters, J. |
author_facet | Vanderbeke, L. Van Mol, P. Van Herck, Y. De Smet, F. Humblet-Baron, S. Martinod, K. Antoranz, A. Arijs, I. Boeckx, B. Bosisio, F. M. Casaer, M. Dauwe, D. De Wever, W. Dooms, C. Dreesen, E. Emmaneel, A. Filtjens, J. Gouwy, M. Gunst, J. Hermans, G. Jansen, S. Lagrou, K. Liston, A. Lorent, N. Meersseman, P. Mercier, T. Neyts, J. Odent, J. Panovska, D. Penttila, P. A. Pollet, E. Proost, P. Qian, J. Quintelier, K. Raes, J. Rex, S. Saeys, Y. Sprooten, J. Tejpar, S. Testelmans, D. Thevissen, K. Van Buyten, T. Vandenhaute, J. Van Gassen, S. Velásquez Pereira, L. C. Vos, R. Weynand, B. Wilmer, A. Yserbyt, J. Garg, A. D. Matthys, P. Wouters, C. Lambrechts, D. Wauters, E. Wauters, J. |
author_sort | Vanderbeke, L. |
collection | PubMed |
description | Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the triggering of an aberrant host immune response, more so than on direct virus-induced cellular damage. To elucidate the immunopathology underlying COVID-19 severity, we perform cytokine and multiplex immune profiling in COVID-19 patients. We show that hypercytokinemia in COVID-19 differs from the interferon-gamma-driven cytokine storm in macrophage activation syndrome, and is more pronounced in critical versus mild-moderate COVID-19. Systems modelling of cytokine levels paired with deep-immune profiling shows that classical monocytes drive this hyper-inflammatory phenotype and that a reduction in T-lymphocytes correlates with disease severity, with CD8+ cells being disproportionately affected. Antigen presenting machinery expression is also reduced in critical disease. Furthermore, we report that neutrophils contribute to disease severity and local tissue damage by amplification of hypercytokinemia and the formation of neutrophil extracellular traps. Together our findings suggest a myeloid-driven immunopathology, in which hyperactivated neutrophils and an ineffective adaptive immune system act as mediators of COVID-19 disease severity. |
format | Online Article Text |
id | pubmed-8257697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82576972021-07-23 Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity Vanderbeke, L. Van Mol, P. Van Herck, Y. De Smet, F. Humblet-Baron, S. Martinod, K. Antoranz, A. Arijs, I. Boeckx, B. Bosisio, F. M. Casaer, M. Dauwe, D. De Wever, W. Dooms, C. Dreesen, E. Emmaneel, A. Filtjens, J. Gouwy, M. Gunst, J. Hermans, G. Jansen, S. Lagrou, K. Liston, A. Lorent, N. Meersseman, P. Mercier, T. Neyts, J. Odent, J. Panovska, D. Penttila, P. A. Pollet, E. Proost, P. Qian, J. Quintelier, K. Raes, J. Rex, S. Saeys, Y. Sprooten, J. Tejpar, S. Testelmans, D. Thevissen, K. Van Buyten, T. Vandenhaute, J. Van Gassen, S. Velásquez Pereira, L. C. Vos, R. Weynand, B. Wilmer, A. Yserbyt, J. Garg, A. D. Matthys, P. Wouters, C. Lambrechts, D. Wauters, E. Wauters, J. Nat Commun Article Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the triggering of an aberrant host immune response, more so than on direct virus-induced cellular damage. To elucidate the immunopathology underlying COVID-19 severity, we perform cytokine and multiplex immune profiling in COVID-19 patients. We show that hypercytokinemia in COVID-19 differs from the interferon-gamma-driven cytokine storm in macrophage activation syndrome, and is more pronounced in critical versus mild-moderate COVID-19. Systems modelling of cytokine levels paired with deep-immune profiling shows that classical monocytes drive this hyper-inflammatory phenotype and that a reduction in T-lymphocytes correlates with disease severity, with CD8+ cells being disproportionately affected. Antigen presenting machinery expression is also reduced in critical disease. Furthermore, we report that neutrophils contribute to disease severity and local tissue damage by amplification of hypercytokinemia and the formation of neutrophil extracellular traps. Together our findings suggest a myeloid-driven immunopathology, in which hyperactivated neutrophils and an ineffective adaptive immune system act as mediators of COVID-19 disease severity. Nature Publishing Group UK 2021-07-05 /pmc/articles/PMC8257697/ /pubmed/34226537 http://dx.doi.org/10.1038/s41467-021-24360-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Vanderbeke, L. Van Mol, P. Van Herck, Y. De Smet, F. Humblet-Baron, S. Martinod, K. Antoranz, A. Arijs, I. Boeckx, B. Bosisio, F. M. Casaer, M. Dauwe, D. De Wever, W. Dooms, C. Dreesen, E. Emmaneel, A. Filtjens, J. Gouwy, M. Gunst, J. Hermans, G. Jansen, S. Lagrou, K. Liston, A. Lorent, N. Meersseman, P. Mercier, T. Neyts, J. Odent, J. Panovska, D. Penttila, P. A. Pollet, E. Proost, P. Qian, J. Quintelier, K. Raes, J. Rex, S. Saeys, Y. Sprooten, J. Tejpar, S. Testelmans, D. Thevissen, K. Van Buyten, T. Vandenhaute, J. Van Gassen, S. Velásquez Pereira, L. C. Vos, R. Weynand, B. Wilmer, A. Yserbyt, J. Garg, A. D. Matthys, P. Wouters, C. Lambrechts, D. Wauters, E. Wauters, J. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity |
title | Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity |
title_full | Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity |
title_fullStr | Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity |
title_full_unstemmed | Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity |
title_short | Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity |
title_sort | monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of covid-19 disease severity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257697/ https://www.ncbi.nlm.nih.gov/pubmed/34226537 http://dx.doi.org/10.1038/s41467-021-24360-w |
work_keys_str_mv | AT vanderbekel monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT vanmolp monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT vanhercky monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT desmetf monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT humbletbarons monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT martinodk monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT antoranza monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT arijsi monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT boeckxb monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT bosisiofm monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT casaerm monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT dauwed monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT deweverw monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT doomsc monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT dreesene monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT emmaneela monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT filtjensj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT gouwym monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT gunstj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT hermansg monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT jansens monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT lagrouk monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT listona monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT lorentn monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT meerssemanp monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT merciert monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT neytsj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT odentj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT panovskad monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT penttilapa monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT pollete monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT proostp monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT qianj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT quintelierk monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT raesj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT rexs monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT saeysy monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT sprootenj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT tejpars monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT testelmansd monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT thevissenk monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT vanbuytent monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT vandenhautej monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT vangassens monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT velasquezpereiralc monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT vosr monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT weynandb monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT wilmera monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT yserbytj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT gargad monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT matthysp monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT woutersc monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT lambrechtsd monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT wauterse monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity AT wautersj monocytedrivenatypicalcytokinestormandaberrantneutrophilactivationaskeymediatorsofcovid19diseaseseverity |